Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 7/20 | 0.33 |
| ▸ | HTR2C | P28335 | 7/20 | 0.33 |
| ▸ | HTR2B | P41595 | 5/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265534 | 0.78 | KCNA3 (0.34) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL8404363 | 0.74 | MAOA (0.38) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL22792757 | 0.72 | HTR2A (0.33) | HTR2AHTR2CHTR2BDRD1 | |
| SCHEMBL14824860 | 0.71 | HTR2A (0.38) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL2048407 | 0.71 | ALDH1A1 (0.42) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL18876065 | 0.71 | MAOA (0.36) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL17221561 | 0.71 | MAOA (0.36) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL4429415 | 0.69 | PAX8 (0.48) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL25696246 | 0.69 | BRD4 (0.32) | — | |
| SCHEMBL22792403 | 0.68 | KCNC1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326124-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326124-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | MAOA 488/4885MAOB 535/4885NFKB1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.